Andere Sprachen Oncternal Therapeutics, Inc.

Aktien

A40063

US68236P2065

ONCT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 02.05.2024			% 5 Tage	% 1. Jan.
8.745 ^USD	+6.00%		+5.49%	-18.45%

18.04.	Oncternal gibt bekannt, dass der erste Patient in der vierten Kohorte der Phase-1/2-Studie von ONCT-534 zur Behandlung von metastasiertem, kastrationsresistentem Prostatakrebs behandelt wurde	CI
15.04.	ONCTERNAL THERAPEUTICS, INC. : HC Wainwright bleibt bei seiner Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results	02.05.
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	01.05.
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	18.04.
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	18.04.
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer	15.03.
Oncternal Therapeutics: Q4 Earnings Snapshot	07.03.
Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07.03.
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results	07.03.
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results	29.02.
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference	06.02.
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	01.02.
Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science	01.02.
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	08.01.
Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	08.01.
Oncternal Therapeutics Announces Reverse Stock Split	04.01.
Oncternal Therapeutics Reports Inducement Award under Nasdaq Listing Rule 5635(4)	03.01.
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	02.01.
Traders Look Ahead to Flat Day After Post-Christmas Rally	27.12.
Top Premarket Decliners	27.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Oncternal Therapeutics, Inc.

Aktien

A40063

US68236P2065

ONCT

Andere Sprachen

Filter